Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure

被引：1
|
作者：
Melani, Christopher [1 ]
Wilson, Wyndham H. [1 ]
机构：
[1] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 03期
关键词：
PHASE-III; R-CHOP; RITUXIMAB; EPOCH; DOXORUBICIN; THERAPY; CYCLOPHOSPHAMIDE; VINCRISTINE; PREDNISONE; OUTCOMES;
D O I：
10.1080/10428194.2021.2002323
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：511 / 513
页数：3
相关论文
共 50 条
  • [1] Front-line management of diffuse large B cell lymphoma
    Cabanillas, Fernando
    [J]. CURRENT OPINION IN ONCOLOGY, 2010, 22 (06) : 642 - 645
  • [2] Failure of front-line autologous transplant in anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma
    Holtan, S. G.
    Feldman, A. L.
    Knudson, R. A.
    Ketterling, R. P.
    Porrata, L. F.
    [J]. BONE MARROW TRANSPLANTATION, 2011, 46 (06) : 904 - 905
  • [3] Failure of front-line autologous transplant in anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma
    S G Holtan
    A L Feldman
    R A Knudson
    R P Ketterling
    L F Porrata
    [J]. Bone Marrow Transplantation, 2011, 46 : 904 - 905
  • [4] Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
    Davies, Andrew
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 284 - 294
  • [5] Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities
    Puckrin, Robert
    Ghosh, Sunita
    Peters, Anthea
    Stewart, Douglas
    [J]. LEUKEMIA & LYMPHOMA, 2022, 63 (03) : 583 - 590
  • [6] Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy
    Farooq, Umar
    Maurer, Matthew J.
    Thompson, Carrie A.
    Thanarajasingam, Gita
    Inwards, David J.
    Micallef, Ivana
    Macon, William
    Syrbu, Sergei
    Lin, Tasha
    Lin, Yi
    Ansell, Stephen M.
    Nowakowski, Grzegorz S.
    Habermann, Thomas M.
    Cerhan, James R.
    Link, Brian K.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (01) : 50 - 60
  • [7] R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
    Al-Sarayfi, Diana
    Meeuwes, Frederik O.
    Durmaz, Mujde
    Issa, Djamila E.
    Brouwer, Rolf E.
    Beeker, Aart
    van Rhenen, Anna
    Mutsaers, Pim G. N. J.
    Bohmer, Lara H.
    van der Poel, Marjolein W. M.
    te Boome, Liane
    van Meerten, Tom
    Chamuleau, Martine E. D.
    Zijlstra, Josee M.
    Brink, Mirian
    Nijland, Marcel
    [J]. BLOOD CANCER JOURNAL, 2022, 12 (09)
  • [8] R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
    Diana Al-Sarayfi
    Frederik O. Meeuwes
    Müjde Durmaz
    Djamila E. Issa
    Rolf E. Brouwer
    Aart Beeker
    Anna van Rhenen
    Pim G. N. J. Mutsaers
    Lara H. Böhmer
    Marjolein W. M. van der Poel
    Liane te Boome
    Tom van Meerten
    Martine E. D. Chamuleau
    Josée M. Zijlstra
    Mirian Brink
    Marcel Nijland
    [J]. Blood Cancer Journal, 12
  • [9] Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma
    Saygin, Caner
    Jia, Xuefei
    Hill, Brian
    Dean, Robert
    Pohlman, Brad
    Smith, Mitchell R.
    Jagadeesh, Deepa
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (10) : 989 - 996
  • [10] Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
    Pirosa, Maria Cristina
    Stathis, Anastasios
    Zucca, Emanuele
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
12345